ArticleThe Lancet. Global health2017
Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries.
Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 6 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Pooled it
- Interventions for tobacco use cessation in people living with HIV.The Cochrane database of systematic reviews · 2024Pooled it
- Factors Influencing Tobacco Smoking and Cessation Among People Living with HIV: A Systematic Review and Meta-analysis.AIDS and behavior · 2024Pooled it
- mHealth Interventions for Treatment Adherence and Outcomes of Care for Cardiometabolic Disease Among Adults Living With HIV: Systematic Review.JMIR mHealth and uHealth · 2021Pooled it
- Changes in smoking patterns after HIV diagnosis or antiretroviral treatment initiation: a global systematic review and meta-analysis.Infectious diseases of poverty · 2020Pooled it
- Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.Progress in cardiovascular diseasesPooled it
- Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial.The Lancet. Global health · 2026Trial
- Usability and cultural adaptation of a text message-based tobacco cessation intervention for people living with HIV in Uganda and Zambia.Addiction science & clinical practice · 2025Trial
- The effect of varenicline on mood and cognition in smokers with HIV.Psychopharmacology · 2020Trial
- Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.Drug and alcohol dependence · 2019Trial
- Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial.Journal of addiction medicineTrial
- Placenta models for HIV-1-ART-nicotine comorbidity research: advances and remaining challenges.Cell death discovery · 2026Review
- Prevalence of tobacco use in a cross-sectional survey of people initiating HIV care in a Chennai clinic.Scientific reports · 2026Article
- CXCL11 levels regulate lung Treg responses to deter the onset of HIV-related COPD.Respiratory research · 2026Article
- Change in self-reported tobacco cessation support practices among HIV providers in Kisumu, Kenya: a pre-post evaluation of a web-based training programme nested within the IN-ToUCH cluster randomised trial.BMJ public health · 2026Article
- Adherence trajectories to nicotine replacement therapy among people living with HIV in Uganda: A secondary analysis of the Quit4LifeTobacco prevention & cessation · 2026Article
- A qualitative investigation of tobacco use and cessation experiences among people living with HIV in Botswana.Discover public health · 2026Article
- Protocol for the Mobile behavioral support plus varenicline for tobacco cessation among people living with HIV in India (MoVIe): A hybrid implementation-effectiveness randomized trial.Contemporary clinical trials · 2026Article
- Tobacco and Cannabis Co-use by HIV Status Among United States Adults: Results from the 2021-2023 National Survey on Drug Use and Health.AIDS and behavior · 2025Article
- The role of alternative reinforcers in smoking outcomes among people with and without HIV.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Observational
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundTobacco use among people living with HIV results in excess morbidity and mortality. However, very little is known about the extent of tobacco use among people living with HIV in low-income and middle-income countries (LMICs). We assessed the prevalence of tobacco use among people living with HIV in LMICs.
methodsWe used Demographic and Health Survey data collected between 2003 and 2014 from 28 LMICs where both tobacco use and HIV test data were made publicly available. We estimated the country-specific, regional, and overall prevalence of current tobacco use (smoked, smokeless, and any tobacco use) among 6729 HIV-positive men from 27 LMICs (aged 15-59 years) and 11 495 HIV-positive women from 28 LMICs (aged 15-49 years), and compared them with those in 193 763 HIV-negative men and 222 808 HIV-negative women, respectively. We estimated prevalence separately for males and females as a proportion, and the analysis accounted for sampling weights, clustering, and stratification in the sampling design. We computed pooled regional and overall prevalence estimates through meta-analysis with the application of a random-effects model. We computed country, regional, and overall relative prevalence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately for males and females to study differences in prevalence rates between HIV-positive and HIV-negative individuals.
findingsThe overall prevalence among HIV-positive men was 24·4% (95% CI 21·1-27·8) for tobacco smoking, 3·4% (1·8-5·6) for smokeless tobacco use, and 27·1% (22·8-31·7) for any tobacco use. We found a higher prevalence in HIV-positive men of any tobacco use (risk ratio [RR] 1·41 [95% CI 1·26-1·57]) and tobacco smoking (1·46 [1·30-1·65]) than in HIV-negative men (both p<0·0001). The difference in smokeless tobacco use prevalence between HIV-positive and HIV-negative men was not significant (1·26 [1·00-1·58]; p=0·050). The overall prevalence among HIV-positive women was 1·3% (95% CI 0·8-1·9) for tobacco smoking, 2·1% (1·1-3·4) for smokeless tobacco use, and 3·6% (95% CI 2·3-5·2) for any tobacco use. We found a higher prevalence in HIV-positive women of any tobacco use (RR 1·36 [95% CI 1·10-1·69]; p=0·0050), tobacco smoking (1·90 [1·38-2·62]; p<0·0001), and smokeless tobacco use (1·32 [1·03-1·69]; p=0·030) than in HIV-negative women.
interpretationThe high prevalence of tobacco use in people living with HIV in LMICs mandates targeted policy, practice, and research action to promote tobacco cessation and to improve the health outcomes in this population.
fundingSouth African Medical Research Council and the UK Medical Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.